We are monitoring the impact of COVID-19 on APAC Cancer Immunotherapy Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1339
Share on
Share on

Asia Pacific Cancer Immunotherapy Market Research Report – Segmented By Application, Product Type, Mode of Administration, End Users, Country (India, China, Japan, Australia, New Zealand, ASEAN Countries and Rest of APAC) - Industry Analysis, Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1339
Pages: 132

Asia Pacific Cancer Immunotherapy Market Size (2021 to 2026)

The size of the Cancer Immunotherapy Market in the Asia Pacific is predicted to be growing at a CAGR of 13.20% from 2021 to 2026. The market size is estimated to be USD 32.74 billion by 2026 and USD 17.61 billion in 2021.

The factors driving the growth of the cancer immunotherapy market are the increasing incidence of cancer, technological advances in therapies, increasing research and development used in cancer treatment, and a wide range of treatments. India and China are significant contributors to APAC, launching new and advanced drugs. In 2012, 6.7 million cancer cases were registered in the APAC region, which is increasing continuously. The specificity and effectiveness of cancer immunotherapy used in breast, skin, and other cancers. During the analysis period, healthcare spending growth and medical insurance are expected to drive APAC Cancer Immunotherapy Market growth.

The lack of experienced medical professionals has limited the growth of the APAC Cancer Immunotherapy Market. Also, the significant loss of new product development is another factor restraining market growth.

The APAC Cancer Immunotherapy Market is expected to face several challenges throughout the forecast period. The emergence of the latest technologies in the medical sector is likely to bolster the market demand. Increasing disposable income in urban areas is also a factor leveraging the growth of the market. 

The lack of knowledge and awareness are the challenges in the APAC Cancer Immunotherapy Market.

This research report on the APAC Cancer Immunotherapy Market has been segmented & sub-segmented into the following categories:

By Type of Therapies: 

  • Immune System Modulators
  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies

By Area of Therapy: 

  • Blood Cancer
  • Prostate Cancer
  • Melanoma
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Other Minor Areas

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, The Asia Pacific region will experience the fastest growth during the forecast period. New advanced immunotherapy drugs are being launched in China and Japan. Numerous clinical trials are underway in these countries/regions. New drug molecules and combination therapies approved by the FDA have been obtained. The approval of new treatments by China and Japan drives immunotherapy in the treatment of cancer. Some market participants such as AstraZeneca, Merck, and Pfizer are investing heavily, expanding the Asia Pacific market.

The Chinese Cancer Immunotherapy Market is projected to be the second-largest country for cancer immunotherapy drugs due to increasing government assistance, growing economy, and the increasing amount spent on healthcare surge the growth of this region. In 2015, in China, around 4.2 new cases of cancer were recorded. In addition, the adoption of sedentary lifestyles and changes in food habits are mainly enhancing the demand of this market to the extent.

The Indian Cancer Immunotherapy Market is expected to have a considerable growth rate in the cancer immunotherapy drugs market. Advanced technologies in manufacturing drugs, a growing patient population, increasing older people, and rising investments from government and other private organizations in the medical field fuel the market's demand.

KEY MARKET PARTICIPANTS:

Companies playing a leading role in the APAC cancer immunotherapy Market are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co. and Celgene Corp, Immunomedics.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Application                 

                                5.1.1 Introduction           

                                5.1.2 Breast       

                                5.1.3 Lung          

                                5.1.4 Melanoma              

                                5.1.5 Colorectal

                                5.1.6 Head & Neck          

                                5.1.7 Prostate   

                                5.1.8 Others      

                                5.1.9 Y-o-Y Growth Analysis, By Application         

                                5.1.10 Market Attractiveness Analysis, By Application     

                                5.1.11 Market Share Analysis, By Application      

                5.2 Product Type                             

                                5.2.1 Introduction           

                                5.2.2 Monoclonal Antibodies     

                                5.2.3 Checkpoint inhibitors/immune modulators              

                                5.2.4 Therapeutic cancer vaccines            

                                5.2.5 Oncolytic virus immunotherapy     

                                5.2.6 Cytokines

                                5.2.7 Adoptive T cell transfer     

                                5.2.8 Adjuvant Immunotherapy

                                5.2.9 Interferons             

                                5.2.10 Interleukins         

                                5.2.11 BCG         

                                5.2.12 Others   

                                5.2.13 Y-o-Y Growth Analysis, By Product Type   

                                5.2.14 Market Attractiveness Analysis, By Product Type

                                5.2.15 Market Share Analysis, By Product Type  

                5.3 Mode of Administration                        

                                5.3.1 Introduction           

                                5.3.2 Intravenous           

                                5.3.3 Oral            

                                5.3.4 Topical      

                                5.3.5 Intra Vesical           

                                5.3.6 Y-o-Y Growth Analysis, By Mode of Administration

                                5.3.7 Market Attractiveness Analysis, By Mode of Administration              

                                5.3.8 Market Share Analysis, By Mode of Administration

                5.3 End users                    

                                5.3.1 Introduction           

                                5.3.2 Hospitals  

                                5.3.3 Clinics        

                                5.3.4 Y-o-Y Growth Analysis, By End users            

                                5.3.5 Market Attractiveness Analysis, By End users           

                                5.3.6 Market Share Analysis, By End users            

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Application

                                                6.1.3.3 By Product Type

                                                6.1.3.4 By Mode of Administration

                                                6.1.3.5 By End users

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Application

                                                6.1.4.3 By Product Type

                                                6.1.4.4 By Mode of Administration

                                                6.1.4.5 By End users

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Application

                                                6.1.5.3 By Product Type

                                                6.1.5.4 By Mode of Administration

                                                6.1.5.6 By End users

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 F. Hoffmann-La Roche Ltd                    

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Amgen                         

                8.3 Viralytics                      

                8.4 Novartis Pharmaceuticals Corporation                            

                8.5 Pfizer                            

                8.6 GlaxoSmithKline Pharmaceuticals Limited                     

                8.7 AstraZeneca plc                        

                8.8 Medivation                

                8.9 Advaxis                        

                8.10 Bristol-Myers Squibb                           

                8.11 Merck & Co. and Celgene Corp                        

                8.12 Immunomedics                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  2. Asia-Pacific Breast Market, By Region, From 2021 to 2026 (USD Billion)
  3. Asia-Pacific Lung Market, By Region, From 2021 to 2026 (USD Billion)
  4. Asia-Pacific Melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  5. Asia-Pacific Colorectal Market, By Region, From 2021 to 2026 (USD Billion)
  6. Asia-Pacific Head & Neck Market, By Region, From 2021 to 2026 (USD Billion)
  7. Asia-Pacific Prostate Market, By Region, From 2021 to 2026 (USD Billion)
  8. Asia-Pacific Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  9. Asia-Pacific Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  10. Asia-Pacific Checkpoint inhibitors/immune modulators Market, By Region, From 2021 to 2026 (USD Billion)
  11. Asia-Pacific Therapeutic cancer vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  12. Asia-Pacific Oncolytic virus immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  13. Asia-Pacific Cytokines Market, By Region, From 2021 to 2026 (USD Billion)
  14. Asia-Pacific Adoptive T cell Transfer Market, By Region, From 2021 to 2026 (USD Billion)
  15. Asia-Pacific Adjuvant immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  16. Asia-Pacific Interferons Market, By Region, From 2021 to 2026 (USD Billion)
  17. Asia-Pacific Interleukins Market, By Region, From 2021 to 2026 (USD Billion)
  18. Asia-Pacific BCG Market, By Region, From 2021 to 2026 (USD Billion)
  19. Asia-Pacific Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  20. Asia-Pacific Intravenous Market, By Region, From 2021 to 2026 (USD Billion)
  21. Asia-Pacific Oral Market, By Region, From 2021 to 2026 (USD Billion)
  22. Asia-Pacific Topical Market, By Region, From 2021 to 2026 (USD Billion)
  23. Asia-Pacific Intravesical Market, By Region, From 2021 to 2026 (USD Billion)
  24. Asia-Pacific Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  25. Asia-Pacific hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  26. Asia-Pacific Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  27. Japan Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  28. Japan Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  29. Japan Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  30. Japan Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  31. China Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  32. China Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  33. China Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  34. China Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  35. India Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  36. India Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  37. India Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  38. India Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  39. South korea Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  40. South korea Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  41. South korea Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  42. South korea Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  43. Australia Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  44. Australia Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  45. Australia Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  46. Australia Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample